TMH (The Medical House)extends ASI autoinjector deal:
This article was originally published in Clinica
Executive Summary
UK-based drug delivery specialist The Medical House (TMH) has extended its development, licence and supply agreement for its ASI disposable autoinjector with an unnamed pharmaceutical company. The deal, which was originally signed as a five-year collaboration in December 2006, now has an initial supply period of a minimum of six years, with an option to extend to up to 16 years. The company has revised its revenue projections for the deal - the Sheffield-headquartered business now expects to earn £34m ($71.3m). TMH will receive £3m in pre-commercialisation licence fees (which is included in the revenue forecast), £2m of which will be paid immediately and the remaining £1m being paid in quarterly payments until April 2009.